À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - À¯Çüº°, Ä¡·áº°, ¿¬·Éº°, ÃÖÁ¾»ç¿ëÀÚº°
Europe Myopia Treatment Market Forecast to 2030 - Regional Analysis - by Type, Treatment, Age Group, and End User
»óǰÄÚµå : 1562247
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 114 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,749,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,126,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,503,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº 2022³â 25¾ï 1,879¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2030³â¿¡´Â 47¾ï 4,613¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 8.2%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

±Ù½Ã Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀ» ÁÖµµ

±Ù½Ã Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ±Ù½Ã Ä¡·á ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù ½ÃÀå ºÐ¼®¿¡ µû¸£¸é ±Ù½Ã °ü¸® Àü·«¿¡ ´ëÇÑ ÀνÄ, ƯÈ÷ ºÎ¸ð¿Í ¾È°ú Àü¹®°¡µé »çÀÌ¿¡¼­ ±Ù½Ã °ü¸® Àü·«¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ±Ù½Ã ´ëÃ¥ÀÇ ½ÇÇàÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¼¼°è ¾È°ú ÀÇ·áÀÇ ¼±µÎÁÖÀÚÀÎ ÀÌ È¸»ç´Â ±¹³» ÃÖ°íÀÇ °Ë¾ÈÇб³ 3°÷°ú Á¦ÈÞÇØ 2024³âºÎÅÍ ±Ù½Ã È®´ë Ä¡·á¸¦ ½Ã¹üÀûÀ¸·Î Á¦°øÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ÀÎ½Ä °³¼± Ä·ÆäÀÎ, ±³À° ÀÌ´Ï¼ÅÆ¼ºê, ±¤¹üÀ§ÇÑ ¿¬±¸ Á¶»ç·Î °ü¸®µÇÁö ¾Ê´Â ±Ù½ÃÀÇ ÀáÀçÀû ¿µÇâ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Àû±ØÀûÀÎ ±Ù½Ã °ü¸® Á¢±Ù¹ýÀ¸·ÎÀÇ ÀüȯÀÌ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ±Ù½Ã Ä¡·á ±â¼ú, Áï ±Ù½Ã ±³Á¤¼ú°ú ¾à¹° ÁßÀç µîÀÇ ±Ù½Ã Ä¡·á ±â¼úÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, ±× °á°ú Áö³­ 2³â°£ ½ÃÀå ±Ô¸ð°¡ 25% ÀÌ»ó ¼ºÀåÇß½À´Ï´Ù. ±Ù½Ã¸¦ °øÁߺ¸°Ç ¹®Á¦·Î ÀνÄÇÏ°í ±Ù½Ã °ü¸® ¼Ö·ç¼ÇÀÇ ½ÇÇà °¡´É¼ºÀ» ÃËÁøÇϱâ À§ÇÑ Á¾ÇÕÀûÀÎ ³ë·ÂÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí Àû±ØÀûÀÎ ½Ã·Â °ü¸® ¹®È­¸¦ Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ð¸àÅÒÀº ±Ù½Ã Ä¡·áÀÇ ¹ßÀüÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, ±Ù½Ã °ü¸® ¹× Ä¡·á Àü·«ÀÇ Àü¸ÁÀ» Çü¼ºÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå °³¿ä

À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå¿¡´Â µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ ¹× ±âŸ À¯·´¿¬ÇÕ ½ÃÀåÀÌ Æ÷ÇԵ˴ϴÙ. À¯·´Àº ¼¼°è ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ Áß¿äÇÑ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È °ßÁ¶ÇÑ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀº ³ëÀÎ Àα¸ÀÇ Áõ°¡, À¯·´ ³» ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ÀÌ Áö¿ª ³» Á¦Ç° µµÀÔ Áõ°¡¿¡ ±âÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µ¶ÀÏÀº ³ë·É Àα¸°¡ Å©°Ô Áõ°¡Çϰí ÀÖ¾î ´« °Ç°­º¸Á¶Á¦ äÅÃÀÌ Áõ°¡ÇÒ ¼ö ÀÖ´Â ÁÁÀº ±âȸ·Î, 'World Population Ageing 2017'¿¡ µû¸£¸é 2017³â µ¶ÀÏ Àüü Àα¸ÀÇ ¾à 28%°¡ 60¼¼ ÀÌ»óÀ̸ç, 2050³â±îÁö ¾à 37.6%±îÁö Áõ°¡ÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. Áõ°¡ÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ Æò±Õ ¼ö¸íÀº ¿©¼ºÀº 83¼¼, ³²¼ºÀº 78¼¼°¡ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ Æò±Õ ¼ö¸íÀÇ ¿¬ÀåÀº ´« °Ç°­¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ±Ã±ØÀûÀ¸·Î ¿¹Ãø ±â°£ µ¿¾È µ¶ÀÏ ±Ù½Ã Ä¡·á ½ÃÀåÀ» °ßÀÎÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå ¼¼ºÐÈ­

À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº À¯Çü, Ä¡·á, ¿¬·É´ë, ÃÖÁ¾»ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

À¯Çüº°·Î À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº °íµµ ±Ù½Ã, ÅðÇ༺ ±Ù½Ã, ÁøÇ༺ ±Ù½Ã·Î ±¸ºÐµÇ¸ç, 2022³â À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº °íµµ ±Ù½Ã ºÐ¾ß°¡ °¡Àå ÄǽÀ´Ï´Ù.

Ä¡·á Ãø¸é¿¡¼­ À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº Àú¿ë·® ¾ÆÆ®·ÎÇÉ Á¡¾ÈÁ¦, ÄÜÅÃÆ®·»Áî, Ortho-K, ±¼Àý±³Á¤¼ö¼ú·Î ±¸ºÐµË´Ï´Ù. Àú¿ë·® ¾ÆÆ®·ÎÇÉ Á¡¾ÈÁ¦ ºÎ¹®Àº 2022³â À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ, ±¼Àý ¼ö¼ú ºÎ¹®Àº ¶ó½Ä ¹× PRK·Î ¼¼ºÐÈ­µË´Ï´Ù.

¿¬·É´ëº°·Î À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº ¼ºÀÎ ±Ù½Ã¿Í ¼Ò¾Æ ±Ù½Ã·Î ³ª´¹´Ï´Ù. ¼ºÀÎ ±Ù½Ã ºÎ¹®Àº 2022³â À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ ´õ Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, Àü¹® Ŭ¸®´Ð, ±¼Àý ±³Á¤ ¼ö¼ú ¼¾ÅÍ·Î ºÐ·ùµÇ¸ç, 2022³â À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÀÌÅ»¸®¾Æ, ÇÁ¶û½º, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ºÐ·ùµË´Ï´Ù. µ¶ÀÏÀº 2022³â À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²À» µ¶Â÷ÁöÇß½À´Ï´Ù.

Alcon AG, Bausch Health Companies Inc, Carl Zeiss AG, CooperVision Inc, Eyes Vision SL, Haag-Streit AG, Johnson & Johnson Vision Care Inc, Nidek Co Ltd. Ziemer Ophthalmic Systems AG µîÀÌ À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷µéÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå »óȲ

Á¦5Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå ±Ù½Ã Ä¡·á ½ÃÀå : À¯·´ ½ÃÀå ºÐ¼®

Á¦7Àå ±Ù½Ã Ä¡·á À¯·´ ½ÃÀå ºÐ¼® : À¯Çüº°

Á¦8Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : Ä¡·áº°

Á¦9Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : ¿¬·ÉÃþº°

Á¦10Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå : ±¹°¡º° ºÐ¼®

Á¦12Àå ¾÷°è »óȲ

Á¦13Àå ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Europe myopia treatment market was valued at US$ 2,518.79 million in 2022 and is expected to reach US$ 4,746.13 million by 2030; it is estimated to register a CAGR of 8.2% from 2022 to 2030.

Increased Awareness of Myopia Treatment drives Europe Myopia Treatment Market

The heightened awareness of myopia treatment options drives the substantial growth of the myopia treatment market. A recent market analysis revealed that the increasing awareness of myopia management strategies, particularly among parents and eyecare professionals, has led to a significant upsurge in implementing myopia control measures. The leader in global eye care is teaming up with three of the best optometry schools in the country to provide extended myopia therapy to a pilot group starting in 2024. As awareness campaigns, educational initiatives, and extensive research studies continue to shed light on the potential consequences of unmanaged myopia, there has been a notable shift toward proactive myopia management approaches. This trend has furthered the adoption of myopia treatment technologies, such as orthokeratology and pharmaceutical interventions, resulting in a remarkable increase in the market size, which has grown by over 25% in the last two years. The collective efforts to raise awareness about myopia as a public health concern and to promote the viability of myopia management solutions are propelling market growth and fostering a culture of proactive vision care. This momentum is likely to continue driving advancements in myopia treatment, emphasizing the pivotal role of awareness in shaping the landscape of myopia management and treatment strategies.

Europe Myopia Treatment Market Overview

The Europe myopia treatment market includes the consolidated markets for Germany, France, the UK, Spain, Italy, and the Rest of Europe. Europe occupies a significant position in the global myopia treatment market and is estimated to register a robust growth rate during the forecast period. The market growth in the region is expected due to the increasing geriatric population, rising emphasis on preventive care in Europe, and rising number of product introductions in the region. Germany's extensively increasing geriatric population represents a lucrative opportunity for increased adoption of eye health supplements in the country. As per the "World Population Ageing 2017," in 2017, ~28% of the total population of Germany was aged 60 or more, and it is estimated to rise to nearly 37.6% by the year 2050. It also mentioned that life expectancy is projected to be 83 years for women and 78 years for men. Such higher life expectancy will likely impact eye health, eventually driving the Germany myopia treatment market during the forecast period.

Europe Myopia Treatment Market Revenue and Forecast to 2030 (US$ Million)

Europe Myopia Treatment Market Segmentation

The Europe myopia treatment market is categorized into type, treatment, age group, end user, and country.

Based on type, the Europe myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest Europe myopia treatment market share in 2022.

In terms of treatment, the Europe myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest Europe myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.

By age group, the Europe myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger Europe myopia treatment market share in 2022.

Based on end user, the Europe myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest Europe myopia treatment market share in 2022.

Based on country, the Europe myopia treatment market is categorized into Germany, the UK, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe myopia treatment market share in 2022.

Alcon AG, Bausch Health Companies Inc, Carl Zeiss AG, CooperVision Inc, Eyes Vision SL, Haag-Streit AG, Johnson & Johnson Vision Care Inc, Nidek Co Ltd, and Ziemer Ophthalmic Systems AG are among the leading companies operating in the Europe myopia treatment market.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Europe Myopia Treatment Market Landscape

5. Europe Myopia Treatment Market - Key Market Dynamics

6. Myopia Treatment Market - Europe Market Analysis

7. Europe Myopia Treatment Market Analysis - by Type

8. Europe Myopia Treatment Market Analysis - by Treatment

9. Europe Myopia Treatment Market Analysis - by Age Group

10. Europe Myopia Treatment Market Analysis - by End User

11. Europe Myopia Treatment Market - Country Analysis

12. Industry Landscape

13. Company Profiles

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â